Survivin Expression in Ovarian Cancer
Author Information
Author(s): Ferrandina G, Legge F, Martinelli E, Ranelletti F O, Zannoni G F, Lauriola L, Gessi M, Gallotta V, Scambia G
Primary Institution: Catholic University of the Sacred Heart
Hypothesis
The study investigates the association of survivin expression with prognosis and other apoptosis-related biological factors in ovarian cancer patients.
Conclusion
The immunohistochemical assessment of survivin status does not seem to be helpful in the prognostic characterization of ovarian cancer.
Supporting Evidence
- Cytoplasmic survivin was observed in 84.5% of cases.
- Nuclear survivin positivity was higher in cases subjected to primary tumor cytoreduction.
- Serous tumors showed a lower percentage of nuclear survivin positivity compared to other histotypes.
Takeaway
The study looked at a protein called survivin in ovarian cancer and found that it doesn't help predict how patients will do.
Methodology
Immunohistochemistry was performed on tumor samples to assess survivin expression and its correlation with clinical parameters.
Potential Biases
Potential biases may arise from the single-institution study design and the selection of patients.
Limitations
The study may be limited by the heterogeneity of the patient population and the methods used to assess survivin expression.
Participant Demographics
The median age of participants was 58.5 years, with 82.7% being stage III–IV ovarian cancer patients.
Statistical Information
P-Value
0.004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website